Early Cardioprotective Effect of Sevoflurane
1 other identifier
interventional
32
1 country
1
Brief Summary
In vitro studies and in vivo animal experiments have shown that halogenated volatile anesthetics have a protective effect on the ischemic myocardium. In clinical settings however, anesthetic preconditioning may be of more interest. The aim of our study was to evaluate the cardioprotective effect of sevoflurane in patients undergoing off-pump coronary artery bypass surgery. We proposed that a cardioprotective effect of sevoflurane would save myocardial function, which we measured acceleration by esophageal Doppler and cardiac index with bolus thermodilution methods, both during brief ischemia and reperfusion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4 coronary-artery-disease
Started Aug 2006
Shorter than P25 for phase_4 coronary-artery-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2006
CompletedFirst Submitted
Initial submission to the registry
May 22, 2007
CompletedFirst Posted
Study publicly available on registry
May 24, 2007
CompletedMay 24, 2007
May 1, 2007
May 22, 2007
May 23, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate cardiac function with measuring of hemodynamic parameters
Measurements were performed at the following intervals: 5 minutes after anesthesia induction; at the beginning of ischemia; 15 minutes after ischemia; 15 minutes after sternum closure
Interventions
Eligibility Criteria
You may qualify if:
- the degree I or II of Cardiac Anesthesia Risk Evaluation score
- angiographically verified coronary artery disease
- left ventricular ejection fraction higher than 40%
You may not qualify if:
- atrioventricular conduction disturbances
- previously ventricular arrhythmias requiring antiarrhythmic treatment
- atrial fibrillation with rapid ventricular response
- myocardial infarction or stroke within 6 months
- diabetes mellitus
- end-stage of obstructive or restrictive pulmonary disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Dubrava
Zagreb, 10000, Croatia
Related Publications (1)
Huseidzinovic I, Barisin S, Bradic N, Milanovic R. Early cardioprotective effect of sevoflurane on left ventricular performance during coronary artery bypass grafting on a beating heart: randomized controlled study. Croat Med J. 2007 Jun;48(3):333-40.
PMID: 17589976DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ino Husedzinovic, MD PhD Prof
Anesthesiology and Intensive Medicine
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 22, 2007
First Posted
May 24, 2007
Study Start
August 1, 2006
Study Completion
December 1, 2006
Last Updated
May 24, 2007
Record last verified: 2007-05